Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of May 21, 2026, KURA trades at $10.31 with a market cap of $816.72M and a P/E ratio of -3.19. KURA moved +15.29% today. Year to date, KURA is +8.39%; over the trailing twelve months it is +62.07%. Its 52-week range spans $5.41 to $19.94. Analyst consensus is strong buy with an average price target of $28.13. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kura Oncology Reports Q1 KOMZIFTI Launch Drives Revenue Growth, Extends Cash Runway: Kura Oncology reported first-quarter 2026 net product revenue driven by its February launch of KOMZIFTI, with prescription uptake in resistant hematologic cancers. The company ended March with sufficient cash to fund operations into 2027 and advanced its farnesyltransferase inhibitor and other candidates into new clinical studies.
| Metric | Value |
|---|---|
| Price | $10.31 |
| Market Cap | $816.72M |
| P/E Ratio | -3.19 |
| EPS | $-3.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.94 |
| 52-Week Low | $5.41 |
| Volume | 39.87K |
| Avg Volume | 0 |
| Revenue (TTM) | $67.48M |
| Net Income | $-278.67M |
| Gross Margin | 0.00% |
10 analysts cover KURA: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.13.